Anti-11[E]-pyroglutamate-modified amyloid β antibodies cross-react with other pathological Aβ species: Relevance for immunotherapy
Authors:
- 1 December 2010
- journal article
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 229 (1-2) , 248-255
Abstract
No abstract availableKeywords
This publication has 45 references indexed in Scilit:
- Mimotopes of conformational epitopes in fibrillar β-amyloidJournal of Neuroimmunology, 2004
- Massive CA1/2 Neuronal Loss with Intraneuronal and N-Terminal Truncated Aβ42 Accumulation in a Novel Alzheimer Transgenic ModelThe American Journal of Pathology, 2004
- Passive Amyloid Immunotherapy Clears Amyloid and Transiently Activates Microglia in a Transgenic Mouse Model of Amyloid DepositionJournal of Neuroscience, 2004
- Alzheimer's Disease Aβ Vaccine Reduces Central Nervous System Aβ Levels in a Non-Human Primate, the Caribbean VervetThe American Journal of Pathology, 2004
- Dominant and differential deposition of distinct β-amyloid peptide species, AβN3(pE), in senile plaquesNeuron, 1995
- Relative abundance of Alzheimer A beta amyloid peptide variants in Alzheimer disease and normal aging.Proceedings of the National Academy of Sciences, 1994
- Mass spectrometry of purified amyloid beta protein in Alzheimer's disease.Journal of Biological Chemistry, 1992
- Isolation and quantification of soluble Alzheimer's β-peptide from biological fluidsNature, 1992
- Amyloid plaque core protein in Alzheimer disease and Down syndrome.Proceedings of the National Academy of Sciences of the United States of America, 1985
- Clinical diagnosis of Alzheimer's diseaseNeurology, 1984